检索结果 - Hongfu Cai

Refine Results
  1. 1

    Sugemalimab combined with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis 由 Hongfu Cai, Ling Fang, Zhiwei Zheng

    发表在 Frontiers in Pharmacology (2024-06-01)
    获取全文
    文件


  2. 2

    Cemiplimab combined with chemotherapy chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis 由 Gaofeng Zhu, Hongfu Cai, Zhiwei Zheng

    获取全文
    文件


  3. 3

    Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract canc... 由 Zhiwei Zheng, Ling Fang, Hongfu Cai

    发表在 BMC Cancer (2023-09-01)
    获取全文
    文件


  4. 4

    Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis 由 Hongfu Cai, Lisheng Huang, Zhiwei Zheng

    发表在 Frontiers in Public Health (2024-07-01)
    获取全文
    文件


  5. 5

    Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer 由 Zhiwei Zheng, Hongcai Chen, Hongfu Cai

    发表在 Frontiers in Oncology (2024-01-01)
    获取全文
    文件


  6. 6

    First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis 由 Ling Fang, Zhiwei Zheng, Hongfu Cai

    发表在 BMJ Open (2023-12-01)
    获取全文
    文件


  7. 7

    Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis 由 Hongfu Cai, Ling Fang, Jingwen Lin, Zhiwei Zheng

    发表在 Frontiers in Pharmacology (2024-10-01)
    获取全文
    文件


  8. 8

    Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis 由 Zhiwei Zheng, Yuxuan Lin, Yuxuan Lin, Hongfu Cai

    发表在 Frontiers in Public Health (2024-03-01)
    获取全文
    文件


  9. 9

    Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis 由 Zhiwei Zheng, Hongfu Cai, Jingwen Lin, Huide Zhu

    发表在 BMJ Open (2024-12-01)
    获取全文
    文件


  10. 10

    Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 1... 由 Zhiwei Zheng, Jingrong Lin, Huide Zhu, Hongfu Cai

    发表在 Frontiers in Public Health (2022-06-01)
    获取全文
    文件


  11. 11

    Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer... 由 Zhiwei Zheng, Liu Yang, Siqi Xu, Huide Zhu, Hongfu Cai

    发表在 Frontiers in Pharmacology (2022-09-01)
    获取全文
    文件


  12. 12

    First-line nivolumab plus ipilimumab or chemotherapy chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis 由 Xueqiong Cao, Hongfu Cai, Na Li, Bin Zheng, Zhiwei Zheng, Maobai Liu

    获取全文
    文件


  13. 13

    Cost-effectiveness analysis of nivolumab plus ipilimumab chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma 由 Liu Yang, Xueqiong Cao, Na Li, Bin Zheng, Maobai Liu, Hongfu Cai

    获取全文
    文件


  14. 14

    Systematic review and meta-analysis: de novo combination of nucleos(t)ide analogs and pegylated interferon alpha versus pegylated interferon alpha monotherapy for the functional cu... 由 Na Wei, Bin Zheng, Hongfu Cai, Na Li, Jing Yang, Maobai Liu

    发表在 Frontiers in Pharmacology (2024-07-01)
    获取全文
    文件


  15. 15

    Unsupervised disparity-tolerant algorithm for terahertz image stitching 由 Xiaojin Wu, Fan Bai, Lun Li, Yuan Gao, Wencheng Wang, Hongfu Cai

    发表在 Scientific Reports (2025-08-01)
    获取全文
    文件


  16. 16

    Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US... 由 Wanxian Zeng, Wanxian Zeng, Xueqiong Cao, Xueqiong Cao, Jingwen Lin, Jingwen Lin, Bin Zheng, Bin Zheng, Na Li, Na Li, Maobai Liu, Maobai Liu, Hongfu Cai, Hongfu Cai

    发表在 Frontiers in Oncology (2023-12-01)
    获取全文
    文件


  17. 17

    Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma 由 Jingwen Lin, Xiaobing Song, Wu Fu, Caicong You, Na Li, Maobai Liu, Hongfu Cai

    获取全文
    文件


  18. 18

    Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review an... 由 Liu Yang, Maobai Liu, Xueqiong Cao, Na Li, Bin Zheng, Jianhao Deng, Hongfu Cai

    获取全文
    文件


  19. 19

    Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer 由 Jiahao Zhang, Jianying Lei, Caicong You, Wu Fu, Bin Zheng, Hongfu Cai, Maobai Liu, Na Li

    发表在 Scientific Reports (2025-01-01)
    获取全文
    文件


  20. 20

    Effect of low-dose aspirin on reducing cardiovascular events and mortality in individuals with CKD stages 3–5: a meta-analysis of randomized controlled trials 由 Jingwen Lin, Xueqiong Cao, Wu Fu, Liu Yang, Wanxian Zeng, Na Li, Maobai Liu, Hongfu Cai

    发表在 BMC Cardiovascular Disorders (2025-04-01)
    获取全文
    文件


检索工具: